Comparative Pharmacology
Head-to-head clinical analysis: ALOPRIM versus DUZALLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOPRIM versus DUZALLO.
ALOPRIM vs DUZALLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
Adults: 200 mg orally twice daily.
None Documented
None Documented
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor